Opthea Presents Wet AMD Program at Innovate Retina
Ticker: OPTEY · Form: 6-K · Filed: Oct 10, 2024 · CIK: 1815620
Sentiment: neutral
Topics: conference-presentation, drug-development, ophthalmology
TL;DR
Opthea's wet AMD drug program to be featured at Innovate Retina conference.
AI Summary
Opthea Limited announced on October 10, 2024, that its wet AMD program will be presented at the Innovate Retina conference. This presentation will likely cover updates on their development of therapies for wet age-related macular degeneration.
Why It Matters
This presentation offers a platform for Opthea to showcase progress in its wet AMD program, potentially attracting investor interest and highlighting advancements in treating a leading cause of vision loss.
Risk Assessment
Risk Level: low — This filing is an informational update regarding a conference presentation and does not contain significant financial or operational changes.
Key Players & Entities
- Opthea Limited (company) — Registrant
- Innovate Retina (company) — Conference where program will be presented
- October 10, 2024 (date) — Filing date and announcement date
FAQ
What specific data or updates regarding Opthea's wet AMD program will be presented at Innovate Retina?
The filing states that the 'Opthea Wet AMD Program' will be presented, but does not specify the exact data or updates to be shared.
When is the Innovate Retina conference scheduled to take place?
The filing does not specify the date of the Innovate Retina conference.
What is the primary focus of Opthea Limited's research and development?
Opthea Limited's primary focus is on the development of therapies for serious eye diseases, including wet age-related macular degeneration (AMD).
What form type is this SEC filing?
This SEC filing is a Form 6-K.
Where is Opthea Limited's principal executive office located?
Opthea Limited's principal executive office is located at Level 4, 650 Chapel Street, South Yarra, Victoria, 3141, Australia.
Filing Stats: 152 words · 1 min read · ~1 pages · Grade level 13.3 · Accepted 2024-10-10 06:02:41
Filing Documents
- opt_-_opthea_wetamd_inno.htm (6-K) — 23KB
- opt-ex99_1.htm (EX-99.1) — 19KB
- img260626642_0.jpg (GRAPHIC) — 61KB
- img260626642_1.jpg (GRAPHIC) — 61KB
- 0000950170-24-113944.txt ( ) — 211KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized. OPTHEA LIMITED (Registrant) By: /s/ Frederic Guerard Name: Frederic Guerard Title: Chief Executive Officer Date: 10/10/2024